Clinical trials: Hyperkinetic Disorders
ADHD, ADD
Efficacy, Tolerability and Safety of Dexmethylphenidate HCl Extended-Release Capsules in Children With Attention-Deficit/Hyperactivity Disorder
The purpose of this study is to determine which dosages of dexmethylphenidate HCl extended-release capsules may represent effective treatment for ADHD in children 6-12 years of age.
- Trial name
- NCT00301236
- Testing
- Dexmethylphenidate HCl extended-release capsules
- Where
- 25 sites in United States
- Volunteers
- 252 people
- Sponsor
- Novartis
Attention Deficit Hyperactivity Disorder
Guiding Dose Increases in Patients Incompletely Responsive to Usual Doses of Atomoxetine
The purpose of this trial is to test the value of dose increases in patients with residual ADHD symptoms after treatment with the usual target dose of atomoxetine
- Trial name
- NCT00485407
- Testing
- Atomoxetine Hydrochloride
- Where
- 2 sites in United States, Canada
- Volunteers
- 377 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
Atomoxetine Hydrochloride Versus Placebo in Taiwanese Children and Adolescents With ADHD
The purpose of this protocol is to investigate the acute treatment efficacy, safety, and tolerability of atomoxetine on a once-daily dosing strategy in Taiwanese children and adolescents with ADHD.
- Trial name
- NCT00485459
- Testing
- Atomoxetine Hydrochloride
- Where
- Taiwan
- Volunteers
- 106 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Disorder With Hyperactivity
Safety and Efficacy of SPD503 in Treating ADHD in Children and Adolescents Aged 6-17
The purpose of this study is to determine the efficacy of SPD503 compared to placebo in the treatment of children and adolescents aged 6-17 with ADHD.
- Trial name
- NCT00150618
- Testing
- SPD503 (1 mg), SPD503 (2 mg), SPD503 (3 mg)
- Volunteers
- 324 people
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder
Lab School Day Study for CONCERTA of Older Children With ADHD
The purpose of this trial is to determine if the study medication, CONCERTA (methylphenidate HCl), is safe and effective in improving academic performance and behavior in children with attention deficit hyperactivity disorder…
- Trial name
- NCT00799409
- Where
- 2 sites in United States
- Volunteers
- 78 people
- Sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC
Attention-Deficit/Hyperactivity Disorder
Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)
The purpose of this study is to investigate the treatment effectiveness of Adhansia XR at month-2 after initiation, and the effectiveness of Adhansia XR overall and when compared with the active comparator group (Concerta) over…
- Trial name
- RE-DAX (NCT04507204)
- Testing
- Adhansia XR, Concerta
- Where
- 35 sites in United States
- Volunteers
- 267 people
- Sponsor
- Purdue Pharma LP
Attention-Deficit/Hyperactivity Disorder
Long Term Safety and Tolerability Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
The objective of this study is to evaluate the long-term effects and tolerability of ABT-089 in adults with Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT00686933
- Testing
- ABT-089
- Where
- 12 sites in United States
- Volunteers
- 117 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Attention-Deficit/Hyperactivity Disorder (ADHD)
Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.
This study will evaluate the efficacy and safety of Dex-Methylphenidate Extended Release 30 mg compared to 20 mg in pediatric patients ages 6-12 with Attention-Deficit Hyperactivity Disorder (ADHD) in a 12-hour laboratory…
- Trial name
- NCT00776009
- Testing
- Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR)
- Where
- 8 sites in United States
- Volunteers
- 165 people
- Sponsor
- Novartis Pharmaceuticals